|
|
Cimzia - News Articles
-
-
FDA?????IL-6??????????TNF-a??????????,?????UCB???Cimzia(certolizumab pegol,?????),??????Enbrel(????),???Humira(?????),Centocor Ortho???? ...
-
-
B-MS conceded in its submission that its drug would not be cost-effective for second-line use when compared with the subcutaneously injected therapies Humira (adalimumab; Abbott), Enbrel (etanercept; Amgen/Pfizer) and Cimzia (certolizumab pegol; UCB) suggesting instead that Orencia should be pitted against Remicade (infliximab; Johnson & Johnson/Merck), the only other intravenous option ...
-
-
Doliveux said last month that after 2011, UCB wasn't expected to face major patent expiries for more than a decade, with its Cimzia, Vimpat and Neupro treatments driving growth for the company, as well as further growth foreseen from new products. ...
-
-
The Company’s technologies have contributed to the success of marketed antibody products, including LUCENTIS (ranibizumab injection) for wet age-related macular degeneration and CIMZIA (certolizumab pegol) for rheumatoid arthritis and Crohn’s ...
-
-
Children and adolescents taking these medications, such as Merck & Co Inc.'s and Johnson & Johnson's Remicade and Simponi, Amgen Inc.'s Enbrel, Abbott Laboratories Inc.'s Humira or UCB SA's Cimzia, were previously warned by the FDA of their increased risk of lymphomas and other cancers. Since TNF blockers operate by suppressing the immune system, it is expected that ...
-
-
Cimzia®, (Certolizumab pegol), el fármaco de UCB Pharma, que constituye el primer y único fármaco biológico anti-TNF PEGilado sin región Fc para el tratamiento de adultos con AR activa de moderada a grave, ha sido galardonado con el Premio "Mejores ...
-
-
The Company’s technologies have contributed to the success of marketed antibody products, including LUCENTIS (ranibizumab injection) for wet age-related macular degeneration and CIMZIA (certolizumab pegol) for rheumatoid arthritis and Crohn’s ...
-
-
The Company’s technologies have contributed to the success of marketed antibody products, including LUCENTIS (ranibizumab injection) for wet age-related macular degeneration and CIMZIA (certolizumab pegol) for rheumatoid arthritis and Crohn’s ...
-
-
2010 sales of recombinant monoclonal antibodies and fusion proteins targeting tumor necrosis factor alpha (TNF) are presented for Enbrel (etanercept), Remicade (infliximab), Humira (adalimumab), Cimzia (certolizumab pegol) and Simponi (golimumab) from Amgen, Wyeth, Takeda Pharmaceuticals, Centocor (J&J), Schering-Plough, Tanabe Seiyaku, Abbott, Eisai and UCB. Other Anti-Inflammatory Antibodies 2010 sales of ...
-
-
Although the overall numbers are relatively small, certolizumab pegol was associated with significantly higher odds of serious infections compared to etanercept, adalimumab, abatacept, anakinra, golimumab, infliximab, and rituximab. Abatacept was significantly less likely than infliximab and tocilizumab to be associated with serious infections.Abatacept, adalimumab, etanercept and golimumab ...
-
-
The syringe and its secondary components were designed for use with UCB's CIMZIA® (certolizumab pegol), a prescription medication for adults with moderately to severely active rheumatoid arthritis or adults with moderately to severely active Crohn's ...
-
-
The pharmaceutical company saw rising demand for key products such as Cimzia, Vimpat and Neupro in the last 12 months, which helped to drive its annual revenue up by two percent year-on-year to 3.22 billion euros (2.77 billion pounds). During the year, the firm was able to meet clinical milestones on time across all of its new developmental ...
-
-
UCB has been presented with a prestigious industry award for the design and packaging of its prefilled syringe offering for the rheumatoid arthritis drug Cimzia. The pharmaceutical company and its manufacturing partner OXO have been honoured with the Good Design Award by the Chicago Athenaeum Museum of Architecture and Design and the European Centre for Architecture Art ...
-
-
CIMZIA : Le certolizumab pegol est un fragment Fab' d'anticorps humanisé recombinant, dirigé contre le facteur de nécrose tumorale alpha (TNFa), ...
-
-
Methods: The construct validity and reliability of the SIAQ were tested in patients with rheumatoid arthritis who volunteered to inject certolizumab pegol using a standard syringe during an open-label multinational extension trial of the long-term safety and efficacy of this drug. ...
-
-
will build in-house biotech microbial manufacturing capacity in Bulle, Switzerland, to secure demand for its core product, Cimzia (certoluzimab pegol). The new manufacturing unit should be operational in 2015 and requires an investment of EUR 250 million. People Notes ...
-
-
LUCENTIS (ranibizumab injection) for wet age-related macular degeneration and CIMZIA (certolizumab pegol) for rheumatoid arthritis and Crohn's disease. ...
-
-
Of the 85, 69 experienced the skin lesions while taking one of three anti-TNF-a drugs: Remicade (infliximab), Humira (adalimumab), or Cimzia (certolizumab). ...
-
-
LUCENTIS (ranibizumab injection) for wet age-related macular degeneration and CIMZIA (certolizumab pegol) for rheumatoid arthritis and Crohn's disease. ...
-
-
"The median ACR hybrid score of 19.99 indicates that at least half of the patients treated with certolizumab pegol plus [methotrexate] had at least a 20% mean improvement in core set measures at week one of treatment," they explained. By week 12, at which time ...
Pages:
1
2
3
4
5
6
...
Next
|
|
